Investments
1343Funds
38Partners & Customers
6Service Providers
3About 3i Group
3i (LSE: III) is a multinational private equity and venture capital company. 3i invests in across a wide range of sectors, with specialist global teams in Oil, Gas and Power, Technology, Media, Business Services, Healthcare, Consumer, General Industrial, and Financial Services.

Want to inform investors similar to 3i Group about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing 3i Group
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find 3i Group in 1 Expert Collection, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Latest 3i Group News
May 13, 2023
Organisation Index term Non-destructive particle counting ten23 health and Bionter collaborate to improve testing of particulates in sterile products. ten23 health, a global contract development and manufacturing organization, and Bionter, a premium supplier of analytical testing technology, announced today their collaboration to advance innovative testing methods of particulate matter. > Bionter has launched EVE, a fully automated particle testing system, to assess sub-visible particulate contamination for parenteral drug applications based on light obscuration. > ten23 health has been running customer samples on an EVE system and is also acting as an application center for Bionter. > Due to the non-destructive nature of Bionters EVE particle testing equipment, the same sample can be further analyzed with orthogonal analyzing methods whilst minimizing sample volume needed. > The Bionter installation complements ten23 healths comprehensive method and equipment panel for the characterization and assessment of aggregates and particulates, including light obscuration, automated flow imaging, nano-tracking analysis (NTA), Dynamic or Static light scattering stand-alone or coupled with chromatographic separation techniques, as well as identification of visible particles by spectroscopic methods. Dr. Björn Boll, Senior Director for Particle Characterization and Drug Product Design at ten23 health commented: We are excited to offer this new technology to our customers. It offers several advantages over established methods that could improve workflows due to automation and reduction of sample consumption. Dr. Tobias Werk, CEO of Bionter, stated: We strive to develop innovative solutions for our customers. The partnership with ten23 gives us insight into the daily challenges of biologics analytics and allows and inspires us to further tailor our solutions to the true needs. About ten23 health ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Our second site, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested worldclass industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting peoples health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner. About Bionter Bionter is a Swiss-based Biotech start-up. Since the foundation in 2020, Bionter has established successful prototype testing with 4 global Pharma companies, received successful seed funding from a US investor and launched their first product in Europe and the US. The team has significant experience in particle analytics as well as the commercialization of biotech products. Bionters first product, EVE, is a fully automated particulate matter detection system, that works non-destructive with the sample used and is fully compliant with current regulations. Bionter is a premium supplier of analytical testing solutions and contributes to the benefit of peoples health by helping pharma companies and their service providers to bring drugs faster and safer to the market. Media contacts: Bionter: Angelika Schrems, angelika.schrems@bionter.com; +41 77 266 53 96 3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021
3i Group Investments
1,343 Investments
3i Group has made 1,343 investments. Their latest investment was in VakantieDiscounter as part of their Private Equity on July 7, 2022.

3i Group Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/11/2022 | Private Equity | VakantieDiscounter | Yes | 1 | ||
6/16/2022 | Private Equity - II | Digital Barriers | Yes | 3i Group, and Volpi Capital | 1 | |
6/7/2022 | Private Equity | Xsuite | Yes | 3i Group, and PINOVA Capital | 2 | |
3/18/2022 | Private Equity - II | |||||
1/27/2022 | Private Equity |
Date | 7/11/2022 | 6/16/2022 | 6/7/2022 | 3/18/2022 | 1/27/2022 |
---|---|---|---|---|---|
Round | Private Equity | Private Equity - II | Private Equity | Private Equity - II | Private Equity |
Company | VakantieDiscounter | Digital Barriers | Xsuite | ||
Amount | |||||
New? | Yes | Yes | Yes | ||
Co-Investors | 3i Group, and Volpi Capital | 3i Group, and PINOVA Capital | |||
Sources | 1 | 1 | 2 |
3i Group Acquisitions
192 Acquisitions
3i Group acquired 192 companies. Their latest acquisition was Konges Slojd on June 20, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/20/2022 | Acq - Fin | 2 | ||||
12/1/2021 | Acq - Fin | 1 | ||||
11/9/2020 | Acq - Fin | 2 | ||||
9/22/2020 | Private Equity | |||||
7/28/2020 |
Date | 6/20/2022 | 12/1/2021 | 11/9/2020 | 9/22/2020 | 7/28/2020 |
---|---|---|---|---|---|
Investment Stage | Private Equity | ||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acq - Fin | Acq - Fin | Acq - Fin | ||
Sources | 2 | 1 | 2 |
3i Group Fund History
38 Fund Histories
3i Group has 38 funds, including 3i Venice.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
12/19/2019 | 3i Venice | Diversified Private Equity | Open | $425.24M | 1 |
4/16/2018 | 3i European Operational Projects Fund | REAL Assets | Closed | $529.28M | 1 |
4/11/2018 | European Operational Projects Fund | $563.8M | 1 | ||
9/15/2016 | Harvest XV CLO | ||||
5/13/2016 | Harvest CLO XV |
Closing Date | 12/19/2019 | 4/16/2018 | 4/11/2018 | 9/15/2016 | 5/13/2016 |
---|---|---|---|---|---|
Fund | 3i Venice | 3i European Operational Projects Fund | European Operational Projects Fund | Harvest XV CLO | Harvest CLO XV |
Fund Type | Diversified Private Equity | REAL Assets | |||
Status | Open | Closed | |||
Amount | $425.24M | $529.28M | $563.8M | ||
Sources | 1 | 1 | 1 |
3i Group Partners & Customers
6 Partners and customers
3i Group has 6 strategic partners and customers. 3i Group recently partnered with AutoRek on November 11, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/8/2017 | Vendor | United Kingdom | 3i Selects AutoRek to Enhance Controls and Governance of Asset Records - bobsguide.com Today , AutoRek , the leading software solutions provider for financial controls , data management and regulatory reporting , announces that 3i Group plc , an international investment manager , has selected AutoRek to enhance controls and automation of asset records to support its continued growth . | 1 | |
6/12/2012 | Vendor | ||||
2/27/2012 | Partner | ||||
2/23/2010 | Partner | ||||
8/28/2008 | Partner |
Date | 11/8/2017 | 6/12/2012 | 2/27/2012 | 2/23/2010 | 8/28/2008 |
---|---|---|---|---|---|
Type | Vendor | Vendor | Partner | Partner | Partner |
Business Partner | |||||
Country | United Kingdom | ||||
News Snippet | 3i Selects AutoRek to Enhance Controls and Governance of Asset Records - bobsguide.com Today , AutoRek , the leading software solutions provider for financial controls , data management and regulatory reporting , announces that 3i Group plc , an international investment manager , has selected AutoRek to enhance controls and automation of asset records to support its continued growth . | ||||
Sources | 1 |
3i Group Service Providers
9 Service Providers
3i Group has 9 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Acq - Fin, Acq - Fin - II, and Private Equity | Investment Bank | Financial Advisor | |
Service Provider | |||
---|---|---|---|
Associated Rounds | Acq - Fin, Acq - Fin - II, and Private Equity | ||
Provider Type | Investment Bank | ||
Service Type | Financial Advisor |
Partnership data by VentureSource
3i Group Team
69 Team Members
3i Group has 69 team members, including current Chief Executive Officer, Simon Borrows.
Name | Work History | Title | Status |
---|---|---|---|
Simon Borrows | Kester Capital | Chief Executive Officer | Current |
Name | Simon Borrows | ||||
---|---|---|---|---|---|
Work History | Kester Capital | ||||
Title | Chief Executive Officer | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.